Wird geladen...
Update on the role of brentuximab vedotin in classical Hodgkin lymphoma
Brentuximab vedotin (BV) is an effective and well-tolerated treatment for patients with classical Hodgkin lymphoma (HL). It was initially approved by the US FDA for the treatment of HL after failure of autologous hematopoietic stem cell transplant (autoHSCT) or after failure of at least two prior li...
Gespeichert in:
| Veröffentlicht in: | Ther Adv Hematol |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6130098/ https://ncbi.nlm.nih.gov/pubmed/30210755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620718786833 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|